article thumbnail

Hims? Hers? It’s Novo Nordisk’s Semaglutide Market Now

Bill of Health

An FDA announcement that semaglutide injection products, the GLP-1 medication in the blockbuster drugs Wegovy and Ozempic, are no longer in shortage. An FDA announcement that semaglutide injection products, the GLP-1 medication in the blockbuster drugs Wegovy and Ozempic, are no longer in shortage.

FDA 130
article thumbnail

HIMSSCast: Predicting what's next for health IT, mobile tech and health system finances

Healthcare It News

FDA and evolving regulations for digital therapeutics, software as a medical device. Up to 18 million people could lose Medicaid coverage after COVID-19 PHE. Automation, and how it can help clinician burnout and back-office processes. Cybersecurity and the patient safety risks of ransomware.

COVID-19 341
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

7 Behavioral Health Technology Trends to Watch in 2025

HIT Consultant

The FDA is approving digital therapeutics tools (i.e., The Centers for Medicare & Medicaid Services (CMS) added codes for Digital Mental Health Treatment in its 2025 Medicare Physician Fee Schedules. In the meantime, patients and providers will have difficulty discerning what works and what doesn’t. Digital Therapeutics.

FDA 111
article thumbnail

The “Food Wars” and the Courts

Bill of Health

The settlement compelled the tobacco companies to pay billions of dollars to the states to compensate them for Medicaid costs incurred by smokers, placed limits on tobacco advertising, and funded public information efforts. territories, and the District of Columbia. The toddler milk case may sidestep these causation challenges.

article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy 

Bill of Health

Associations Between Copays, Coverage Limits for Naloxone, and Prescribing in Medicaid. Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. FDA validation of surrogate endpoints in oncology: 2005-2022. Subst Abuse.

FDA 241
article thumbnail

Texas District Court Strikes Down FDA’s Laboratory Developed Tests Final Rule Less Than Two Months before Phase I Implementation

Hall Render

Background For decades, LDTsin-house diagnostic tests developed, validated, and performed within a single laboratoryhave been regulated by states and the Centers for Medicare & Medicaid Services (“CMS”) under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), while FDA exercised enforcement discretion.

FDA 52
article thumbnail

Insurance Coverage for Psychedelic Therapy

Bill of Health

By Vincent Joralemon As therapies using drugs like MDMA, psilocybin, and LSD advance through the FDA research and approval pipeline, patients should be prepared for steep price tags attached to these procedures. This is typical—without a seal of approval from FDA, insurers are reluctant to pay for off-label treatments. for depression).

FDA 203